ဤအပိုင်းအကြောင်း
Tighter funding conditions are putting greater pressure on emerging biotech to reach key development milestones quickly while managing limited budgets. That environment is also changing what sponsors expect from their manufacturing partners, driving demand for development models that emphasize speed, predictability, and cost certainty.
In this episode of Off Script, we spoke with Sanjay Konagurthu, PhD, senior director of science and innovation, Pharma Services, at Thermo Fisher Scientific, about how today's funding landscape is influencing manufacturing and development strategies. The conversation explored why emerging biotechs may benefit from fixed-scope development programs, how parallel development activities can shorten timelines without compromising quality, and how CDMOs are adapting their offerings to help sponsors move programs forward more efficiently.
